$KBLB

Kraig Biocraft Laboratories, Inc

CIK:0001413119|SEC Filings

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue
Operating Expenses
General and Administrative	374,381	344,035	869,947	652,886
Professional Fees	69,862	43,625	140,697	106,660
Officer’s Salary	194,821	186,197	387,219	370,927
Research and Development	64,369	63,888	131,070	87,764
Total Operating Expenses	703,433	637,745	1,528,933	1,218,237
Loss from Operations	(703,433)	(637,745)	(1,528,933)	(1,218,237)
Other Income/(Expenses)
Net change in unrealized depreciation on investment in gold bullion	(74,015)	(10,011)	(53,607)	107,477
Interest expense	(151,399)	(141,986)	(299,832)	(282,334)
Gain on sale of gold		62,469		62,469
Interest income	19,312	1,140	30,117	4,459
Total Other Income/(Expenses)	(206,102)	(88,388)	(323,322)	(107,929)
Net (Loss) before Provision for Income Taxes	(909,535)	(726,133)	(1,852,255)	(1,326,166)
Provision for Income Taxes
Net (Loss)	$ (909,535)	$ (726,133)	$ (1,852,255)	$ (1,326,166)
Net Income (Loss) Per Share - Basic	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Net Income (Loss) Per Share - Diluted	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding during the period - Basic	1,110,343,050	1,047,493,242	1,100,659,919	1,044,492,324
Weighted average number of shares outstanding during the period - Diluted	1,110,343,050	1,047,493,242	1,100,659,919	1,044,492,324

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash Flows From Operating Activities:
Net Loss	$ (909,535)	$ (726,133)	$ (1,852,255)	$ (1,326,166)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense	7,102	5,837	13,324	11,520
Net change in unrealized depreciation (appreciation) and depreciation in gold bullions			53,607	(107,477)
Gain on sale of gold bullions				(62,469)
Imputed interest - related party	18,395	20,157	36,790	40,093
Fair value of options issued for services			20,314	8,394
Warrants issued/(cancelled) to consultants			270,446	98,069
Changes in operating assets and liabilities:
(Increase) Decrease prepaid expenses			(2,531)	13,508
(Increase) in inventory			(105,075)
Decrease in operating lease right-of-use, net			33,749	27,662
Increase in accrued expenses and other payables - related party			436,069	413,426
(Decrease) Increase in accounts payable			(504)	34,514
Decrease in operating lease liabilities, current			(32,347)	(28,698)
Net Cash Used In Operating Activities			(1,128,413)	(877,624)
Cah Flows from Investing Activities
Proceeds from sale of investment in gold				147,238
Purchase of fixed assets			(42,724)	(3,783)
Net Cash Provided (Used in) by Investing Activities			(42,724)	143,455
Cash Flows From Financing Activities:
Proceeds from Standby Equity Purchase Agreement			2,772,547	856,367
Payment of debt offering costs				(10,000)
Net Cash Provided by Financing Activities			2,772,547	846,367
Net Change in Cash and Cash Equivalents			1,601,410	112,198
Cash and Cash Equivalents at Beginning of Period			1,790,236	673,264	$ 673,264
Cash and Cash Equivalents at End of Period	$ 3,391,646	$ 785,462	3,391,646	785,462	$ 1,790,236
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Adoption of lease standard ASC 842			55,192
Common shares issued in connection with Standby Equity Purchase Agreement - Commitment Share fee				100,000
Shares issuable in connection with cashless warrant exercise			$ 142,526	$ 79,578

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets
Cash and cash equivalents	$ 3,391,646	$ 1,790,236
Inventory	134,142	29,067
Prepaid expenses	49,057	49,338
Total Current Assets	3,574,845	1,868,641
Property and Equipment, net	54,403	25,003
Investment in gold bullions (cost $241,120 and $450,216, respectively)	440,652	494,259
Operating lease right-of-use asset, net	191,906	170,463
Security deposit	9,986	7,174
Total Assets	4,271,792	2,565,540
Current Liabilities
Operating lease liability, current	72,843	51,909
Total Current Liabilities	10,901,744	10,445,245
Long Term Liabilities
Operating lease liability, net of current	121,164	119,253
Total Liabilities	11,022,908	10,564,498
Commitments and Contingencies (Note 7)
Stockholders’ Deficit
Preferred stock value
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	22,000	22,000
Additional paid-in capital	12,619,910	12,434,886
Accumulated Deficit	(58,561,327)	(56,709,072)
Total Stockholders’ Deficit	(6,751,116)	(7,998,958)
Total Liabilities and Stockholders’ Deficit	4,271,792	2,565,540
Series A Preferred Stock [Member]
Stockholders’ Deficit
Preferred stock value	5,237,800	5,237,800
Common Class A [Member]
Stockholders’ Deficit
Common stock value	33,930,501	31,015,428
Common Class B [Member]
Stockholders’ Deficit
Common stock value
Nonrelated Party [Member]
Current Liabilities
Accounts payable and accrued expenses	504,607	505,111
Related Party [Member]
Current Liabilities
Accounts payable and accrued expenses	8,767,002	8,330,933
Note payable - related party	1,492,000	1,492,000
Royalty agreement payable - related party	$ 65,292	$ 65,292